Advancing Global Solutions to Antimicrobial Resistance (AMR)
Antimicrobial resistance (AMR) is widely recognised as one of the most serious global health threats of the 21st century. Since 2019, the Monash Warwick Alliance (MWA) has made sustained, strategic investments to address this challenge by building research capability, accelerating antibiotic discovery, and training the next generation of AMR scientists.
The program was conceived and led by Professor Greg Challis, University of Warwick and Professor Ana Traven, Monash University, whose complementary scientific expertise formed the intellectual backbone of the initiative. Through their leadership, the program brought together international, interdisciplinary teams focused on revitalising antibiotic discovery and building the skilled workforce required to confront what is increasingly described as the “silent pandemic”.
Antibiotics remain one of the most consequential medical discoveries in human history, underpinning modern healthcare and dramatically extending life expectancy. Yet the rapid rise of resistant bacteria, fungi and parasites now threatens to undermine these gains. Poorly treatable infections linked to AMR contribute to almost five million deaths each year, with projections of 8–10 million annual deaths and up to USD $1 trillion in healthcare costs over the next 25 years if new solutions are not found. Despite this urgency, global antibiotic discovery pipelines have struggled to keep pace. Professors Challis and Traven recognised that addressing this gap would require not only scientific innovation, but sustained investment in people, platforms and international collaboration.
Through the Monash Warwick Alliance, this vision was translated into action. MWA acted as a strategic partner and initial funder, providing the framework, resources and institutional connectivity that enabled the academic leaders to scale their ambitions beyond individual laboratories. By backing an integrated program rather than isolated projects, MWA enabled Professors Challis and Traven to align discovery science, translational research and training across two continents, creating a cohesive and durable AMR research ecosystem.
Under their academic leadership, the program trained 10 early‑career research scientists alongside doctoral, masters and Honours students, equipping them with interdisciplinary skills spanning chemistry, microbiology, synthetic biology, and infection biology. Researchers benefited from international exchanges between Monash and Warwick, direct transfer of technologies and methods, and participation in highly competitive development initiatives such as the Interdisciplinary Course on Antibiotics and Resistance (ICARe) at Les Pensières Center for Global Health and the BRIDGE Commercialisation of Pharmaceutical Research Program at Queensland University of Technology. These opportunities strengthened career trajectories while accelerating the translation of fundamental discoveries into potential therapeutic pathways.
From left to right: Dr Daniel Van (University of Warwick; visiting Research Fellow), Dr Chuan Huang (Monash University), Matt Pledge (MWA PhD student), Callum Bullock (University of Warwick; visiting PhD student), Prof Greg Challis (University of Warwick and Monash University), Dr Lauren Murray (Monash University), Dr Xinyun Jian (Monash University).
The impact of this MWA‑enabled, academically led program is evident in both scientific and institutional outcomes. The teams generated new knowledge, experimental models, tools and technologies that advance antibiotic discovery and AMR research, while also attracting substantial follow‑on investment from leading national and international funders, including the ARC, NHMRC, Wellcome Trust, BBSRC, MRC, JPIAMR, and a Philanthropic donor. The program also contributed directly to the establishment of two enduring research centres: the Centre to Impact AMR at Monash University and the Sir Howard Dalton Centre for Translational Mechanistic Enzymology at the University of Warwick, embedding AMR capability within both institutions for the long term.
Career development outcomes further illustrate the program’s success. One research fellow progressed into the UK’s highly competitive National Health Service Scientist Training Programme at the UK Health Security Agency, highlighting how MWA’s strategic investment, combined with strong academic mentorship, can translate into leadership roles within national health systems.
Recognising that AMR remains under‑appreciated beyond specialist communities, Professors Challis and Traven, supported by the MWA, also prioritised public engagement and advocacy. Their discoveries and insights were communicated through press releases and covered by major outlets including the ABC, The Age, Science Daily, the BBC, The Telegraph and Nature, helping to raise awareness, influence policy conversations and build momentum for continued investment in AMR research.
Overall, this program exemplifies how the Monash Warwick Alliance functions as a powerful enabler of academic excellence. By providing the initial funding for an ambitious, academically led vision, MWA amplified the impact of Professors Challis and Traven and positioned Monash and Warwick at the forefront of global efforts to combat antimicrobial resistance. The legacy is a stronger international partnership, a new generation of highly skilled AMR researchers, and enduring centres of excellence that will continue to deliver global health impact well beyond the life of the initial investment.
Monash Warwick Alliance Professor of Sustainable Chemistry
(Chemical and Synthetic Biology)
University of Warwick
Professor and NHMRC Investigator Fellow in the Biomedicine Discovery Institute
Monash University